Compensatory mutations restore fitness during the evolution of dihydrofolate reductase

Molecular Biology and Evolution

Volumn 27, Issue 12, 2010, Pages 2682-2690

  Brown, Kyle M ^a   Costanzo, Marna S ^a   Xu, Wenxin ^a   Roy, Scott ^b   Lozovsky, Elena R ^a   Hartl, Daniel L ^a  

^a HARVARD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

compensatory mutations; drug resistance; malaria; mutational landscapes; phenotypic robustness

Indexed keywords

DIHYDROFOLATE REDUCTASE;

ALLELE; ANTIFUNGAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FUNGUS GROWTH; GROWTH RATE; NONHUMAN; PHENOTYPE; PLASMODIUM FALCIPARUM; POINT MUTATION; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; TRANSGENE;

ALLELES; ANTIMALARIALS; DRUG RESISTANCE; EVOLUTION, MOLECULAR; GENES, PROTOZOAN; GENETIC FITNESS; MODELS, GENETIC; PHENOTYPE; PLASMODIUM FALCIPARUM; POINT MUTATION; PYRIMETHAMINE; SACCHAROMYCES CEREVISIAE; TETRAHYDROFOLATE DEHYDROGENASE;

PLASMODIUM FALCIPARUM; SACCHAROMYCES CEREVISIAE;

EID: 78649365006     PISSN: 07374038     EISSN: 15371719     Source Type: Journal    
DOI: 10.1093/molbev/msq160     Document Type: Article

References (36)

1. Aharoni A, Gaidukov L, Khersonsky O, Gould SM, Roodveldt C, Tawfik DS. 2005. The 'evolvability' of promiscuous protein functions. Nat Genet. 37:73-76.
2. Andersson DI. 2006. The biological cost of antiobiotic resistance: any practical conclusions Curr Opin Microbiol. 9:461-465.
3. Berkhout B. 1999. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J Biomed Sci. 6:298-305.
4. Björkman J, Hughes D, Andersson DI. 1998. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA. 95:3949-3953.
5. Chusacultanachai S, Thiensathit P, Tarnchompoo B, Sirawaraporn W, Yuthavong Y. 2002. Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli. Mol Biochem Parasitol. 120:61-72.
6. Currie CR, Scott JA, Summerbell RC, Malloch D. 1999. Fungus-growing ants use antibiotic-producing bacteria to control garden parasites. Nature 398:701-704.
7. DePristo MA, Hartl DL, Weinreich DM. 2007. Mutational reversions during adaptive protein evolution. Mol Biol Evol. 24:1608-1610.
8. Ekland EH, Fidlock DA. 2007. Advances in understanding the genetic basis of antimalarial drug resistance. Curr Opin Microbiol. 10:363-370.
9. Foote SJ, Galatis D, Cowman AF. 1990. Amino acids in the dihydrofolate reductase-thymidilate synthase gene of Plamo-dium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA. 87:3014-3017.
10. Gillespie JH. 1984. Molecular evolution over the mutational landscape. Evolution 38:1116-1129.
11. Hackbarth CJ, Kocagoz T, Kocagoz S, Chambers HF. 1995. Point mutations in Staphylococcus aureus PBP2 gene affect penicillin-binding kinetics and are associated with resistance. Antimicrob Agents Chemother. 39:103-106.
12. Hartl DL, Dykhuizen DE, Dean AM. 1985. Limits of adaptation: the evolution of selective neutrality. Genetics 111:655-674.
13. Hunt SY, Detering C, Varani G, Jacobus DP, Schiehser GA, Shieh HM, Nevchas I, Terpinski J, Sibley CH. 2005. Identification of the optimal third generation antifolate against P. falciparum and P. vivax. Mol Biochem Parasitol. 144:198-205.
14. Joseph SB, Hall DW. 2004. Spontaneous mutations in diploid Saccharomyces cerevisiae: more beneficial than expected. Genetics 168:1817-1825.
15. Khersonsky O, Roodveldt C, Tawfik DS. 2006. Enzyme promiscuity: evolutionary and mechanistic aspects. Curr Opin Chem Biol. 10:498-508.
16. Kondrashov FA. 2005. In search of the limits of evolution. Nat Genet. 37:9-10.
17. Laible G, Hackenbeck R, Sicard MA, Joris B, Ghuysen JM. 1989. Nucleotide sequences of pbpX genes encoding penicillin-binding proteins 2x from Streptococcus pneumoniae R6 and a cefotaxime resistant mutant, C506. Mol Microbiol. 3:1337-1348.
18. Lozovsky ER, Chookajorn T, Brown KM, Imwong M, Shaw PJ, Kamchonwongpaisan S, Neafsey DE, Weinreich DM, Hartl DL. 2009. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci USA. 106:12025-12030.
19. Maplestone RA, Stone MJ, Williams DH. 1992. The evolutionary role of secondary metabolites-a review. Gene. 115:151-157.
20. Maisnier-Paitin S, Andersson DI. 2004. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res Microbiol. 155:360-369.
21. Maisnier-Paitin S, Berg OG, Liljas L, Andersson DI. 2002. Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Mol Microbiol. 2: 355-366.
22. Mita T, Tanabe K, Takahashi N, et al. (13 co-authors). 2007. Independent evolution of pyrimethamine resistance in Plasmo-dium falciparum isolates in Melanesia. Antimicrob Agents Chemother. 51:1071-1077.
23. Nair S, Miller B, Barends M, Jaidee A, Patel J, Mayxay M, Newton P, Nosten F, Ferdig MT, Anderson TJ. 2008. Adaptive copy number evolution in malaria parasites. PLoS Genet. 4:e1000243.
24. Nardese V, Gütlich M, Brambilla A, Agostoni ML. 1996. Disruption of the GTP-cyclohydrolase I gene in Saccharomyces cerevisiae. Biochem Biophys Res Comm. 218:273-279.
25. Nirmalan N, Wang P, Sims PFG, Hyde JE. 2002. Transcritional analysis of genes encoding enzymes of the folate pathway in the human malaria parasite Plasmodium falciparum. Mol Microbiol. 46:179-190.
26. Orr HA. 2002. The population genetics of adaptation: the adaptation of DNA sequences. Evolution 56:1317-1330.
27. Palumbi SR. 2001. Humans as the world's greatest evolutionary force. Science 293:1786-1790.
28. Schlitzer M. 2007. Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem 2:944-986.
29. Sibley CH, Brophy VH, Cheesman S, Hamilton KL, Hankins EG, Wooden JM, Kilbey B. 1997. Yeast as a model system to study drugs effective against apicomplexan proteins. Methods 13: 190-207.
30. Sibley CH, Macreadie I. 2001. Novel approaches to tackling malarial drug resistance using yeast. IUBMB Life. 52:285-9.
31. Sikorski RS, Hieter P. 1989. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122:19-27.
32. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. 1997. Antifolate-resistance mutants of Plasmodium falciparum dihydrofolate reductase. Proc Nat Acad Sci USA. 94: 1124-1129.
33. Tawfik DS. 2005. The evolvability of drug resistance: response to Fernandez. J Biomol Struct Dyn. 22:617-619.
34. Weinreich DM, Delaney N, Depristo MA, Hartl DL. 2006. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312:111-114.
35. Wooden JM, Hartwell LH, Vasquez B, Sibley CH. 1997. Analysis in yeast of antimalarial drugs that target the dihydrofolate reductase of Plasmodium falciparum. Mol Biochem Parasitol. 85:25-40.
36. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul J, Sirawaraporn W, Taylor P, Walkinshaw MD, Yuthavong Y. 2003. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol. 10:357-365.